Enterprise Value

39.1B

Cash

1.292B

Avg Qtr Burn

-147.5M

Short % of Float

7.91%

Insider Ownership

0.92%

Institutional Own.

85.40%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PADCEV® Details
Urothelial carcinoma

Approved

Quarterly sales

TUKYSA (Tucatinib) Details
Solid tumor/s, Colorectal cancer , Cancer, Metastatic colorectal cancer

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Phase 3

Update

TUKYSA (Tucatinib) combo Kadcyla Details
Solid tumor/s, Cancer, Breast cancer

Phase 3

Update

ADCETRIS® + pembrolizumab Details
Solid tumor/s, Non-small cell lung carcinoma, Melanoma

Phase 2

Data readout